Tags : LCA10

Allergan and Editas Report First Patient Dosing in P-I/II BRILLIANCE

Shots: The P-I/II study will assess the safety & efficacy of AGN-151587 (subretinal injection) in ~18 patients with Leber congenital amaurosis 10. The patients enrolled are both adult & pediatric patients (aged 3-17yrs.) The first patients dosing in BRILLIANCE study marks a significant milestone toward delivering the CRISPR medicines, treating the devastating LCA10 AGN-151587 (EDIT-101) […]Read More